Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase

Identifieur interne : 003681 ( Main/Exploration ); précédent : 003680; suivant : 003682

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase

Auteurs : Hong-Qiang Gao [États-Unis] ; Paul L. Boyer [États-Unis] ; Stefan G. Sarafianos [États-Unis] ; Edward Arnold [États-Unis] ; Stephen H. Hughes [États-Unis]

Source :

RBID : ISTEX:13EB29C2C5C1362590E910D155C1E10C4C44CC70

English descriptors

Abstract

Abstract: Treating HIV infections with drugs that block viral replication selects for drug-resistant strains of the virus. Particular inhibitors select characteristic resistance mutations. In the case of the nucleoside analogs 3TC and FTC, resistant viruses are selected with mutations at amino acid residue 184 of reverse transcriptase (RT). The initial change is usually to M184I; this virus is rapidly replaced by a variant carrying the mutation M184V. 3TC and FTC are taken up by cells and converted into 3TCTP and FTCTP. The triphosphate forms of these nucleoside analogs are incorporated into DNA by HIV-1 RT and act as chain terminators. Both of the mutations, M184I and M184V, provide very high levels of resistance in vivo; purified HIV-1 RT carrying M184V and M184I also shows resistance to 3TCTP and FTCTP in in vitro polymerase assays. Amino acid M184 is part of the dNTP binding site of HIV-1 RT. Structural studies suggest that the mechanism of resistance of HIV-1 RTs carrying the M184V or M184I mutation involves steric hindrance, which could either completely block the binding of 3TCTP and FTCTP or allow binding of these nucleoside triphosphate molecules but only in a configuration that would prevent incorporation. The available kinetic data are ambiguous: one group has reported that the primary effect of the mutations is at the level of 3TCTP binding; another, at the level of incorporation. We have approached this problem using assays that monitor the ability of HIV-1 RT to undergo a conformational change upon binding a dNTP. These studies show that both wild-type RT and the drug-resistant variants can bind 3TCTP at the polymerase active site; however, the binding to M184V and M184I is somewhat weaker and is sensitive to salt. We propose that the drug-resistant variants bind 3TCTP in a strained configuration that is salt-sensitive and is not catalytically competent.

Url:
DOI: 10.1006/jmbi.2000.3823


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase</title>
<author>
<name sortKey="Gao, Hong Qiang" sort="Gao, Hong Qiang" uniqKey="Gao H" first="Hong-Qiang" last="Gao">Hong-Qiang Gao</name>
</author>
<author>
<name sortKey="Boyer, Paul L" sort="Boyer, Paul L" uniqKey="Boyer P" first="Paul L" last="Boyer">Paul L. Boyer</name>
</author>
<author>
<name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
</author>
<author>
<name sortKey="Arnold, Edward" sort="Arnold, Edward" uniqKey="Arnold E" first="Edward" last="Arnold">Edward Arnold</name>
</author>
<author>
<name sortKey="Hughes, Stephen H" sort="Hughes, Stephen H" uniqKey="Hughes S" first="Stephen H" last="Hughes">Stephen H. Hughes</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13EB29C2C5C1362590E910D155C1E10C4C44CC70</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1006/jmbi.2000.3823</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-RMGL7TXC-5/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001805</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001805</idno>
<idno type="wicri:Area/Istex/Curation">001805</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F80</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F80</idno>
<idno type="wicri:doubleKey">0022-2836:2000:Gao H:the:role:of</idno>
<idno type="wicri:Area/Main/Merge">003723</idno>
<idno type="wicri:Area/Main/Curation">003681</idno>
<idno type="wicri:Area/Main/Exploration">003681</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase</title>
<author>
<name sortKey="Gao, Hong Qiang" sort="Gao, Hong Qiang" uniqKey="Gao H" first="Hong-Qiang" last="Gao">Hong-Qiang Gao</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ABL-Basic Research Program NCI-Frederick Cancer Research and Development Center P.O. Box B, Frederick MD 21702-1201</wicri:regionArea>
<wicri:noRegion>Frederick MD 21702-1201</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Boyer, Paul L" sort="Boyer, Paul L" uniqKey="Boyer P" first="Paul L" last="Boyer">Paul L. Boyer</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ABL-Basic Research Program NCI-Frederick Cancer Research and Development Center P.O. Box B, Frederick MD 21702-1201</wicri:regionArea>
<wicri:noRegion>Frederick MD 21702-1201</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Advanced Biotechnology and Medicine (CABM) and Rutgers University Chemistry Department, 679 Hoes Lane Piscataway, NJ 08854-5638</wicri:regionArea>
<wicri:noRegion>NJ 08854-5638</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Arnold, Edward" sort="Arnold, Edward" uniqKey="Arnold E" first="Edward" last="Arnold">Edward Arnold</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Advanced Biotechnology and Medicine (CABM) and Rutgers University Chemistry Department, 679 Hoes Lane Piscataway, NJ 08854-5638</wicri:regionArea>
<wicri:noRegion>NJ 08854-5638</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hughes, Stephen H" sort="Hughes, Stephen H" uniqKey="Hughes S" first="Stephen H" last="Hughes">Stephen H. Hughes</name>
<affiliation></affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ABL-Basic Research Program NCI-Frederick Cancer Research and Development Center P.O. Box B, Frederick MD 21702-1201</wicri:regionArea>
<wicri:noRegion>Frederick MD 21702-1201</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Journal of Molecular Biology</title>
<title level="j" type="abbrev">YJMBI</title>
<idno type="ISSN">0022-2836</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="2000">2000</date>
<biblScope unit="volume">300</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="403">403</biblScope>
<biblScope unit="page" to="418">418</biblScope>
</imprint>
<idno type="ISSN">0022-2836</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0022-2836</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>3TC</term>
<term>BSA</term>
<term>HIV-1</term>
<term>PR</term>
<term>RNase H</term>
<term>RT</term>
<term>drug resistance</term>
<term>dsDNA</term>
<term>reverse transcriptase</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>3tctp</term>
<term>3tctp binding</term>
<term>Active site</term>
<term>Amino</term>
<term>Analog</term>
<term>Assay</term>
<term>Binary</term>
<term>Biol</term>
<term>Cleavage</term>
<term>Cognate</term>
<term>Cognate dntp</term>
<term>Dctp</term>
<term>Dideoxy</term>
<term>Dideoxy nucleoside</term>
<term>Dntp</term>
<term>Dntps</term>
<term>England biolabs</term>
<term>Feng anderson</term>
<term>Ftctp</term>
<term>Grice</term>
<term>Higher concentration</term>
<term>Higher concentrations</term>
<term>Higher salt conditions</term>
<term>Hindrance</term>
<term>Huang</term>
<term>Human virus</term>
<term>Human virus type</term>
<term>Loading buffer</term>
<term>Mgcl2</term>
<term>Multiple cleavages</term>
<term>Mutant</term>
<term>Mutant enzymes</term>
<term>Mutation</term>
<term>Natl acad</term>
<term>Normal dntp</term>
<term>Normal dntps</term>
<term>Nucleic</term>
<term>Nucleic acid</term>
<term>Nucleoside</term>
<term>Nucleoside analogs</term>
<term>Oligonucleotide</term>
<term>Oligonucleotides</term>
<term>Oxathiolane ring</term>
<term>Polymerase</term>
<term>Polymerase assays</term>
<term>Primary effect</term>
<term>Primer</term>
<term>Primer strand</term>
<term>Resistance figure</term>
<term>Ribose ring</term>
<term>Rnase</term>
<term>Room temperature</term>
<term>Salt concentrations</term>
<term>Shift assay</term>
<term>Shift assays</term>
<term>Steric</term>
<term>Steric hindrance</term>
<term>Template strand</term>
<term>Ternary</term>
<term>Transcriptase</term>
<term>Triphosphate</term>
<term>Various concentrations</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Treating HIV infections with drugs that block viral replication selects for drug-resistant strains of the virus. Particular inhibitors select characteristic resistance mutations. In the case of the nucleoside analogs 3TC and FTC, resistant viruses are selected with mutations at amino acid residue 184 of reverse transcriptase (RT). The initial change is usually to M184I; this virus is rapidly replaced by a variant carrying the mutation M184V. 3TC and FTC are taken up by cells and converted into 3TCTP and FTCTP. The triphosphate forms of these nucleoside analogs are incorporated into DNA by HIV-1 RT and act as chain terminators. Both of the mutations, M184I and M184V, provide very high levels of resistance in vivo; purified HIV-1 RT carrying M184V and M184I also shows resistance to 3TCTP and FTCTP in in vitro polymerase assays. Amino acid M184 is part of the dNTP binding site of HIV-1 RT. Structural studies suggest that the mechanism of resistance of HIV-1 RTs carrying the M184V or M184I mutation involves steric hindrance, which could either completely block the binding of 3TCTP and FTCTP or allow binding of these nucleoside triphosphate molecules but only in a configuration that would prevent incorporation. The available kinetic data are ambiguous: one group has reported that the primary effect of the mutations is at the level of 3TCTP binding; another, at the level of incorporation. We have approached this problem using assays that monitor the ability of HIV-1 RT to undergo a conformational change upon binding a dNTP. These studies show that both wild-type RT and the drug-resistant variants can bind 3TCTP at the polymerase active site; however, the binding to M184V and M184I is somewhat weaker and is sensitive to salt. We propose that the drug-resistant variants bind 3TCTP in a strained configuration that is salt-sensitive and is not catalytically competent.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
</list>
<tree>
<country name="États-Unis">
<noRegion>
<name sortKey="Gao, Hong Qiang" sort="Gao, Hong Qiang" uniqKey="Gao H" first="Hong-Qiang" last="Gao">Hong-Qiang Gao</name>
</noRegion>
<name sortKey="Arnold, Edward" sort="Arnold, Edward" uniqKey="Arnold E" first="Edward" last="Arnold">Edward Arnold</name>
<name sortKey="Boyer, Paul L" sort="Boyer, Paul L" uniqKey="Boyer P" first="Paul L" last="Boyer">Paul L. Boyer</name>
<name sortKey="Hughes, Stephen H" sort="Hughes, Stephen H" uniqKey="Hughes S" first="Stephen H" last="Hughes">Stephen H. Hughes</name>
<name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003681 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003681 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:13EB29C2C5C1362590E910D155C1E10C4C44CC70
   |texte=   The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021